Equities

Aditxt Inc

ADTX:NAQ

Aditxt Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.01
  • Today's Change-0.02 / -0.99%
  • Shares traded10.00
  • 1 Year change-91.60%
  • Beta1.0555
Data delayed at least 15 minutes, as of May 28 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

  • Revenue in USD (TTM)506.45k
  • Net income in USD-41.45m
  • Incorporated2017
  • Employees47.00
  • Location
    Aditxt Inc737 N. Fifth Street, Suite 200RICHMOND 23219United StatesUSA
  • Phone+1 (909) 488-0844
  • Fax+1 (302) 697-4597
  • Websitehttps://aditxt.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ADTX:NAQ since
announced
Transaction
value
Evofem Biosciences IncAnnounced12 Dec 202312 Dec 2023Announced-47.11%100.00m
Data delayed at least 15 minutes, as of May 28 2024 20:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Resonate Blends Inc101.41k-4.72m3.11m6.00------30.68-0.0537-0.05370.0012-0.00070.0328-------152.56-680.29-----34.87-78.88-4,657.83-12,895.26---0.74131.02---66.73-56.57-316.63------
Exicure Inc21.77m2.97m3.12m6.000.21060.69270.80370.14311.711.713.070.521.04----1,674,923.0014.17-41.7542.53-55.57----13.64-302.07----0.00--6,068.1224.2995.97---59.57--
AccuStem Sciences Inc0.00-1.74m3.14m3.00---------0.1537-0.15370.00-0.23090.00----0.00-1,168.46--------------------------45.26------
Bio Path Holdings Inc0.00-13.96m3.16m10.00---------27.39-27.390.00-3.480.00----0.00-216.97-70.80-390.65-76.87---------------------15.94------
Sonoma Pharmaceuticals Inc12.31m-5.08m3.17m9.00--0.4147--0.2571-0.9608-0.96081.950.4890.86252.584.761,367,778.00-35.56-37.52-47.14-51.3539.1740.17-41.23-37.123.11--0.0065--5.10-4.44-1.28--7.54--
Eiger Biopharmaceuticals Inc15.77m-74.96m3.26m25.00------0.2065-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
60 Degrees Pharmaceuticals Inc378.20k-1.07m3.31m2.00------8.76-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Optimus Healthcare Services Inc1.27m-7.79m3.32m17.00------2.62-0.1948-0.19480.0317-0.12910.2595--2.1674,453.53-159.79---2,228.37--77.90---615.77--0.1525-15.4121.18--------------
Aditxt Inc506.45k-41.45m3.35m47.00--0.3371--6.61-109.80-109.800.74885.960.02840.92961.3410,775.53-231.82-192.78-658.00-321.59-27.22---8,149.75-7,208.650.0562-3.420.3915---30.90---18.11------
Livewire Ergogenics Inc67.98k-1.09m3.35m1.00------49.25-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Manuka Inc671.00k-1.14m3.36m4.00------5.01-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
AgriFORCE Growing Systems Ltd16.28k-13.34m3.49m7.00--0.3384--214.31-10.78-10.780.00390.3960.0009--0.4432,325.71-74.39-78.95-100.77-109.8616.58---81,946.25-243,182.500.8186-1.300.1913------8.85--48.61--
Avenue Therapeutics Inc0.00-7.18m3.49m3.00--0.7721-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Zyversa Therapeutics Inc0.00-105.53m3.55m7.00--0.3164-----1,791.54-1,791.540.0013.440.00----0.00-142.87---164.77-------------17,576.860.00-------340.15------
Tharimmune Inc0.00-8.89m3.59m2.00--0.5096-----111.65-111.650.008.970.00----0.00-130.60---173.40--------------0.00-------9.98------
Data as of May 28 2024. Currency figures normalised to Aditxt Inc's reporting currency: US Dollar USD

Institutional shareholders

0.93%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 31 Mar 202414.49k0.74%
Tower Research Capital LLCas of 31 Mar 20242.22k0.11%
Group One Trading LPas of 31 Mar 2024603.000.03%
IFP Advisors, Inc.as of 31 Dec 2023303.000.02%
Natixis Investment Managers International SAas of 31 Mar 2024250.000.01%
UBS Securities LLCas of 31 Mar 2024180.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202437.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202413.000.00%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 202410.000.00%
FSC Securities Corp.as of 30 Sep 202310.000.00%
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.